63E Stock Overview
A medical technology company, develops implantable neuro-stimulation Systems and non-invasive systems for electrical stimulation of specific areas of the spinal cord.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Onward Medical N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.64 |
| 52 Week High | €6.28 |
| 52 Week Low | €2.04 |
| Beta | 0.84 |
| 11 Month Change | -10.08% |
| 3 Month Change | -3.53% |
| 1 Year Change | 15.42% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 63E | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 8.4% | 1.8% |
| 1Y | 15.4% | 8.3% | 13.8% |
Return vs Industry: 63E exceeded the German Medical Equipment industry which returned 8.3% over the past year.
Return vs Market: 63E exceeded the German Market which returned 13.8% over the past year.
Price Volatility
| 63E volatility | |
|---|---|
| 63E Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 63E has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 63E's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 99 | Dave Marver | www.onwd.com |
Onward Medical N.V., a medical technology company, develops implantable neuro-stimulation Systems and non-invasive systems for electrical stimulation of specific areas of the spinal cord. The company engages in developing ARCEX, a transcutaneous system designed to improve upper extremity strength, function, and other symptoms in people with spinal cord injury (SCI); ARCIM, a minimally invasive implantable system to address blood pressure instability and other symptoms in people with SCI; and ARCBCI, which adds an implantable bran-computer interface to the ARCIM to restore thought-driven movement of the upper and lower limbs. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.
Onward Medical N.V. Fundamentals Summary
| 63E fundamental statistics | |
|---|---|
| Market cap | €180.07m |
| Earnings (TTM) | -€35.15m |
| Revenue (TTM) | n/a |
-957.8x
P/S Ratio-5.1x
P/E RatioIs 63E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 63E income statement (TTM) | |
|---|---|
| Revenue | -€188.00k |
| Cost of Revenue | €13.44m |
| Gross Profit | -€13.63m |
| Other Expenses | €21.52m |
| Earnings | -€35.15m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | 7,250.53% |
| Net Profit Margin | 18,697.34% |
| Debt/Equity Ratio | 87.3% |
How did 63E perform over the long term?
See historical performance and comparison